Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Other financing activities (2016 - 2025)

Neuroone Medical Technologies (NMTC) has disclosed Other financing activities for 6 consecutive years, with $22920.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other financing activities rose 7.58% year-over-year to $22920.0, compared with a TTM value of -$96181.0 through Dec 2025, down 2766.51%, and an annual FY2024 reading of $20000.0, down 91.48% over the prior year.
  • Other financing activities was $22920.0 for Q4 2025 at Neuroone Medical Technologies, up from $21305.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $167646.0 in Q1 2023 and bottomed at -$216599.0 in Q3 2024.
  • Average Other financing activities over 4 years is $33216.7, with a median of $37698.0 recorded in 2023.
  • The sharpest move saw Other financing activities soared 139.92% in 2023, then plummeted 43.49% in 2024.
  • Year by year, Other financing activities stood at $15713.0 in 2022, then skyrocketed by 139.92% to $37698.0 in 2023, then tumbled by 43.49% to $21305.0 in 2024, then rose by 7.58% to $22920.0 in 2025.
  • Business Quant data shows Other financing activities for NMTC at $22920.0 in Q4 2025, $21305.0 in Q4 2024, and -$216599.0 in Q3 2024.